Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

January 11, 2020

Study Completion Date

November 18, 2020

Conditions
Epilepsy, Focal Seizures, Partial Seizures
Interventions
DRUG

Natalizumab

As specified in the treatment arm.

OTHER

Placebo

As specified in treatment arms.

Trial Locations (31)

10467

Research Site, The Bronx

13210

Research Site, Syracuse

14642

Research Site, Rochester

19104

Research Site, Philadelphia

20037

Research Site, Washington D.C.

20815

Research Site, Chevy Chase

20817

Research Site, Bethesda

27514

Research Site, Chapel Hill

27705

Research Site, Durham

28806

Research Site, Asheville

29425

Research Site, Charleston

32209

Research Site, Jacksonville

32308

Research Site, Tallahassee

32751

Research Site, Maitland

32803

Research Site, Orlando

33606

Research Site, Tampa

35294

Research Site, Birmingham

44320

Research Site, Akron

48602

Research Site, Saginaw

60612

Research Site, Chicago

63110

Research Site, St Louis

75390

Research Site, Dallas

85004

Research Site, Phoenix

85054

Research Site, Phoenix

90404

Research Site, Santa Monica

92103

Research Site, San Diego

96817

Research Site, Honolulu

98055

Research Site, Renton

02111

Research Site, Boston

02115

Research Site, Boston

08103

Research Site, Camden

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03283371 - Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy | Biotech Hunter | Biotech Hunter